FDA Approves METHOTREXATE — Chartwell RX, LLC

Chartwell RX, LLC announced the FDA approval of its generic methotrexate sodium tablets for the treatment of several conditions, positioning the company to compete in the established oral administration market. This approval allows Chartwell RX to leverage the drug’s widespread usage to potentially capture market share in the chronic condition management sector ahead of brand exclusivity.